369 related articles for article (PubMed ID: 18401431)
21. Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies.
Rittner K; Schreiber V; Erbs P; Lusky M
Cancer Gene Ther; 2007 May; 14(5):509-18. PubMed ID: 17318198
[TBL] [Abstract][Full Text] [Related]
22. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
[TBL] [Abstract][Full Text] [Related]
23. Generation and selection of targeted adenoviruses embodying optimized vector properties.
Noureddini SC; Krendelshchikov A; Simonenko V; Hedley SJ; Douglas JT; Curiel DT; Korokhov N
Virus Res; 2006 Mar; 116(1-2):185-95. PubMed ID: 16293334
[TBL] [Abstract][Full Text] [Related]
24. In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.
Lee CT; Lee YJ; Kwon SY; Lee J; Kim KI; Park KH; Kang JH; Yoo CG; Kim YW; Han SK; Chung JK; Shim YS; Curiel DT; Carbone DP
Cancer Res; 2006 Jan; 66(1):372-7. PubMed ID: 16397251
[TBL] [Abstract][Full Text] [Related]
25. Genetic targeting strategies for adenovirus.
Noureddini SC; Curiel DT
Mol Pharm; 2005; 2(5):341-7. PubMed ID: 16196486
[TBL] [Abstract][Full Text] [Related]
26. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
Petry H; Brooks A; Orme A; Wang P; Liu P; Xie J; Kretschmer P; Qian HS; Hermiston TW; Harkins RN
Gene Ther; 2008 Jan; 15(1):54-60. PubMed ID: 17960164
[TBL] [Abstract][Full Text] [Related]
27. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.
Espenlaub S; Wortmann A; Engler T; Corjon S; Kochanek S; Kreppel F
J Gene Med; 2008 Dec; 10(12):1303-14. PubMed ID: 18837065
[TBL] [Abstract][Full Text] [Related]
28. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
Hoffmann D; Wildner O
Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
[TBL] [Abstract][Full Text] [Related]
29. Effective repeat administration with adenovirus vectors to the muscle.
Chen P; Kovesdi I; Bruder JT
Gene Ther; 2000 Apr; 7(7):587-95. PubMed ID: 10819574
[TBL] [Abstract][Full Text] [Related]
30. Circumventing the immune response to adenovirus-mediated gene therapy.
Kass-Eisler A; Leinwand L; Gall J; Bloom B; Falck-Pedersen E
Gene Ther; 1996 Feb; 3(2):154-62. PubMed ID: 8867863
[TBL] [Abstract][Full Text] [Related]
31. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains.
Henning P; Andersson KM; Frykholm K; Ali A; Magnusson MK; Nygren PA; Granio O; Hong SS; Boulanger P; Lindholm L
Gene Ther; 2005 Feb; 12(3):211-24. PubMed ID: 15510176
[TBL] [Abstract][Full Text] [Related]
32. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon.
Kurachi S; Koizumi N; Sakurai F; Kawabata K; Sakurai H; Nakagawa S; Hayakawa T; Mizuguchi H
Gene Ther; 2007 Feb; 14(3):266-74. PubMed ID: 17006548
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.
Ni S; Gaggar A; Di Paolo N; Li ZY; Liu Y; Strauss R; Sova P; Morihara J; Feng Q; Kiviat N; Touré P; Sow PS; Lieber A
Cancer Gene Ther; 2006 Dec; 13(12):1072-81. PubMed ID: 16874361
[TBL] [Abstract][Full Text] [Related]
34. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.
Ophorst OJ; Kostense S; Goudsmit J; De Swart RL; Verhaagh S; Zakhartchouk A; Van Meijer M; Sprangers M; Van Amerongen G; Yüksel S; Osterhaus AD; Havenga MJ
Vaccine; 2004 Aug; 22(23-24):3035-44. PubMed ID: 15297053
[TBL] [Abstract][Full Text] [Related]
35. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy.
Rahman A; Tsai V; Goudreau A; Shinoda JY; Wen SF; Ramachandra M; Ralston R; Maneval D; LaFace D; Shabram P
Mol Ther; 2001 May; 3(5 Pt 1):768-78. PubMed ID: 11356081
[TBL] [Abstract][Full Text] [Related]
36. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
37. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.
Breidenbach M; Rein DT; Wang M; Nettelbeck DM; Hemminki A; Ulasov I; Rivera AR; Everts M; Alvarez RD; Douglas JT; Curiel DT
Hum Gene Ther; 2004 May; 15(5):509-18. PubMed ID: 15144580
[TBL] [Abstract][Full Text] [Related]
38. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model.
Tsai V; Johnson DE; Rahman A; Wen SF; LaFace D; Philopena J; Nery J; Zepeda M; Maneval DC; Demers GW; Ralston R
Clin Cancer Res; 2004 Nov; 10(21):7199-206. PubMed ID: 15534093
[TBL] [Abstract][Full Text] [Related]
39. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases.
Worth LL; Jia SF; Zhou Z; Chen L; Kleinerman ES
Clin Cancer Res; 2000 Sep; 6(9):3713-8. PubMed ID: 10999765
[TBL] [Abstract][Full Text] [Related]
40. Use of chimeric adenoviral vectors to assess capsid neutralization determinants.
Roy S; Clawson DS; Calcedo R; Lebherz C; Sanmiguel J; Wu D; Wilson JM
Virology; 2005 Mar; 333(2):207-14. PubMed ID: 15721355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
